<DOC>
	<DOCNO>NCT01921010</DOCNO>
	<brief_summary>The combination HDL-C elevation , lower triglyceride LDL-C reduction accomplish addition niacin statin medication would improve endothelial function compare LDL-C reduction alone patient without coronary artery disease combination low HDL-C/high triglyceride . The combination lipid lowering therapy would beneficial effect marker inflammation . These benefit would particularly evident woman .</brief_summary>
	<brief_title>Benefit Elevation HDL-C Women</brief_title>
	<detailed_description />
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Stable CAD ( coronary artery disease ) patient statin therapy LDLC 90135mg/dl triglyceride &gt; 150mg/dl Wellcontrolled diabetes HbA1C &lt; 7.5 currently statin therapy , able tolerate Niacin without unstable blood glucose level LDLC 90135mg/dl triglyceride &gt; 150mg/dl Stable patient statin therapy LDLC 90135mg/dl triglyceride &gt; 150mg/dl History MI ( myocardial infarction ) , PTCA ( percutaneous transluminal coronary angiography ) surgery within previous 3 month Currently Niaspan unwilling withdraw Niaspan therapy know intolerance niacin Active know gall bladder disease Pregnant nursing woman Significant comorbidity precludes participation Significant liver disease , active alcoholism , LFT ( liver function test ) &gt; 1.5x 's ULN ( upper limit normal ) screen Diabetes Hg A1C ( hemoglobin A1c ) &lt; 7.5 PI perceive inability comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>